Share on StockTwits

Stock analysts at Brean Capital started coverage on shares of Chimerix (NASDAQ:CMRX) in a report issued on Tuesday. The firm set a “buy” rating and a $33.00 price target on the stock. Brean Capital’s target price would suggest a potential upside of 53.06% from the company’s current price.

In other Chimerix news, CFO Timothy W. Trost sold 5,000 shares of the stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $22.74, for a total transaction of $113,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Chimerix (NASDAQ:CMRX) traded down 7.70% during mid-day trading on Tuesday, hitting $19.90. The stock had a trading volume of 277,522 shares. Chimerix has a 1-year low of $12.96 and a 1-year high of $27.69. The stock has a 50-day moving average of $20.73 and a 200-day moving average of $19.8. The company’s market cap is $536.6 million.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.36) by $0.03. The company had revenue of $0.78 million for the quarter, compared to the consensus estimate of $0.85 million. During the same quarter last year, the company posted ($22.58) earnings per share. Analysts expect that Chimerix will post $-1.79 EPS for the current fiscal year.

Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.